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Abstract Imaging
Introduction: Radiation induced optic neuropathy is a devastating complication of 
radiotherapy to the anterior visual pathway, resulting in significant, permanent vision loss.
Presentation: A 55-year-old male presented with 5 days of decreased vision in the right eye 
who had previously been treated for squamous cell carcinoma of the face. Ophthalmologic 
examination and MRI showed findings consistent with radiation induced optic neuropathy. 
The patient was treated with high dose IV corticosteroids followed by an oral taper. 
Results: The patient’s baseline vision in the right eye was 20/20 prior the event. On the 
initial presentation the patient’s visual acuity had decreased to only counting fingers in the 
right eye. Immedially following the steroid treatment the patient’s visual acuity had 
improved to 20/40, and two months later was measured to be 20/50.
Conclusions: High dose corticosteroids may play a role in the treatment of radiation induced 
optic neuropathy.
Background
Discussion Conclusions
Radiation of the brain or face can have devastating effects on the eye and the optic 
pathway. Radiation retinopathy is the most commonly seen complication, usually 
presenting between 6 months and 3 years following radiation treatment and is commonly 
monitored for in patients who have received radiation treatment in a region close to the 
eyes. A less commonly seen complication which can cause severe or complete vision loss in 
this patient group is radiation induced optic neuropathy (RION). It most commonly 
presents 10-20 months following treatment, although cases have been documented as much 
as 9 years following treatment.
Both complications have similar factors increasing the risk of occurring after treatment. 
The most significant of which is the cumulative doses of radiation that exceed 50 Gy or 
single doses to the anterior visual pathway of 10 Gy or more. These values vary 
significantly in the literature and cases of radiation retinopathy have been documented with 
as little as 15 Gy of cumulative treatment. Incrased age is also a risk factor in both diseases. 
In the case of RION pre-existing compression of the optic nerve by the tumor has also been 
shown to increase the risk of developing the disease.
The diagnosis of RION is based off clinical findings as well as imaging of the optic 
pathway. Patients will show decreased visual acuity, visual field deficits, and decreased 
color vision. MRI is the imaging modality of choice showing optic nerve enhancement on 
T-1 or T-2 weighted images. 
RION is thought to cause permanent vision loss with no proven beneficial treatment at this 
time. Treatment with corticosteroids and anticoagulation have generally been unsuccessful 
in large case series. There is some evidence of consistent improvement after early treatment 
with hyperbaric oxygen, but the difficulty in obtaining this treatment has limited the 
research in this area.
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A 55-year-old male presented with 5 days of decreased vision in the right eye. Two years 
prior to presentation, he was diagnosed with squamous cell carcinoma of the skin and treated 
with a cumulative radiation dose of 70 Gy. ENT and oncology were monitoring the patient 
for a squamous cell carcinoma of the maxillary sinus without current treatment at that time. 
On ophthalmologic exam, his baseline visual acuity of 20/20 had decreased to counting 
fingers. Dilated fundus exam (Figure 1) and fluorescein angiogram (Figure 2) showed optic 
disc edema and hemorrhage. MRI orbits (Figure 3) showed no interval increase in size of the 
squamous cell carcinoma with slight enhancement of the optic nerve and laboratory workup 
was unremarkable. The patient was diagnosed with radiation induced optic neuropathy. After 
risks and benefits were discussed with the patient, he agreed to a trial of high dose steroid 
therapy. The patient received three days of intravenous solumedrol (1 mg/kg/day), followed 
by a twelve day taper of oral prednisone (starting at 80 mg). Ten days after steroid initiation, 
the patient’s visual acuity improved to 20/40. Two months later, his visual acuity remained 
improved at 20/50. 
• RION is a devastation complication of radiation treatment to the brain or face
• Patients who have need radiation treatment to the face or brain should be warned of 
ocular complications and possible decreased or loss of vision
• There is not a widely accepted treatment at this time, although systemic steroids, anti-
VEGF injections, and hyperbaric oxygen are all being trialed at this time
• As seen with this patient there appears to be a subset of patients that can significantly 
benefit from treatment with high dose corticosteroids
• Further evaluation of recently developed predictive models may allow stratification of 
patients into those that may benefit from treatment with corticosteroids
• Early intervention after presenting symptoms appears to be crucial as seen in this case 
and as documented in the literature
• Treatment with high dose corticosteroids should be considered in all patients presenting 
with RION
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Figure 1.  Fundus Photo of the right eye showing blurred disc 
margins consistent with disc edema (red arrow), a disk 
hemorrhage (blue arrow), and cotton wool spot consistent with 
radiation retinopathy (yellow arrow)
Figure 2.  Fluorescein angiogram showing hyper fluorecence 
and leakage around the optic nerve consistent with disc edema 
(red arrow)
Figure 3. T2 post contrast MRI of the brain and orbits 
showing slight enhancement of the optic nerve within 
the optic canal (red arrow)
Radiation therapy is a widely utilized therapy for treatment of many cancers of the skin of 
the face, the sinuses, and intracranial tumors when adequate resection is not a reasonable or 
possible treatment. Guided radiotherapy can limit the radiation exposure to sensitive tissues 
such as the retina and optic nerve, but radiation retinopathy and radiation induced optic 
neuropathy (RION) are complications of radiation treatment that must be discussed and 
monitored for following treatment. As seen with this patient, the complications may be 
limited as seen with his asymptomatic radiation retinopathy, but the complications may also 
be severe resulting in significantly decreased vision, as he presented with his RION, 
potentially leading to complete loss of vision. These complications commonly occur within 
the first two to three years as in this case, but there are documented cases of patients 
presenting as much as nine years after radiation treatment, highlighting the importance of 
long term ophthalmic monitoring.
Given that the rate of RION is relatively low, there is not a clear consensus at this time 
regarding a definitive treatment modality. Systemic corticosteroids, intra-vitreal anti-VEGF 
injections, and hyperbaric oxygen have all been trialed as potential therapies with mixed 
results and no modality showing consistent benefit. Systemic corticosteroids have been 
approached as a potential therapy given the success that has been seen using them as 
treatment for a cerebral radiation necrosis. However, their success has been limited in the 
treatment of RION and there are some small population retrospective studies showing that 
patients have no signs of benefit from systemic corticosteroid treatment.
Recently a studied was published that performed a retrospective review of 73 patients who 
had received systemic corticosteroid therapy for RION. 38 of the patients had responded to 
treatment with the corticosteroids and 35 of the patients showed no benefit. From this 
patient data a predictive model was created which was able to obtain a high degree of 
accuracy in determining which patients could benefit from treatment. Elevated BUN was 
found to be significantly related to a greater response to treatment. The patient in this case 
had a BUN of 21 at the time of presentation.
The current understanding of RION is limited given its relatively low prevalence. Given 
that there is no clear intervention that has been show to halt or reverse the vision loss in 
affected patients, further research in this area with larger prospective studies is needed. 
Although some studies have dismissed systemic corticosteroids as a potential treatment for 
RION, as seen with this patient there may be a subset that significantly benefit from early 
treatment with high dose corticosteroids.
